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Abstract 
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By 
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May 2010 
Chair:  Rickey Hicks, Ph.D. 
Major Department: Chemistry 
Troponin is an integral protein in the mechanism of muscle contraction.  In order to 
induce cardiac muscle contraction, Ca2+ must bind to the TnC subunit (calcium binding subunit) 
of troponin to begin a conformational change in the protein.  The ATPase rate of myosin with 
actin present is cooperatively activated by Ca2+ and Myosin.  Ca2+ greatly increases the rate of 
ATPase activity (18-fold) and decreases the concentration of actin needed for muscle contraction 
activity. Ca2+ binding to troponin induces a conformational change that leads to a process of 
muscle contraction [8]. 
The focus of our research has been to investigate thermodynamic binding properties of 
various divalent metals to the Troponin C subunit of the cardiac muscle protein using isothermal 
 titration calorimetry.  We have been able to successfully observe Ca2+ binding to the apo form of 
Bovine Cardiac TnC (BVCTnC) as well as the apo form of Human Cardiac TnC (HCTnC).  
Familial Hypertrophic Cardiomyopathy, FHCM, is an autosomal dominant genetic 
disorder.  FHCM causes an abnormal cardiac muscle contraction response in patients afflicted 
with the genetic mutations that result in the disorder.  About 1 in 500 people, 0.2%, are afflicted 
with this disorder.  There are many ways to approach treatment for this disease.  A treatment that 
we have considered uses calcium sensitizing drugs.  Calcium sensitizing drugs allow troponin to 
be more sensitive to the presence of calcium which induces cardiac muscle contraction [31]. 
Another focus of our research is to determine thermodynamic binding properties of 
calcium sensitizing drugs to troponin using isothermal titration calorimetry.  Understanding the 
thermodynamic properties of drug-protein interaction can help reveal the mechanism of action by 
which the drug operates.  These studies will lead to a better understanding of how calcium 
sensitizing drugs interact with troponin and determine their practicality in drug design for 
patients afflicted with familial hypertrophic cardiomyopathies. 
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Chapter 1: An Introduction 
1.1 An Introduction to the Anatomy of the Muscle 
Muscle is the fundamental contractile tissue found in mammals and other organisms.  
Muscle tissue is responsible for an organism’s voluntary movement and force.  The tissue is also 
accountable for some involuntary organ function which requires the power generated from the 
contractile energy provided by the tissue.  The power generated from the muscle tissue is an 
integral part of many organisms’ viability in nature. 
Muscle is composed of a grouping of fibers called a fascicle [1,2].  The fascicle is held 
together by the perimysium.  The perimysium is a connective tissue that holds the muscle’s 
bundle of fibers together [3].  Within this bundle, individual muscle fibers are enclosed by the 
endomysium [3].  The individual muscle fiber that is held together by the endomysium is 
composed of myofibrils [3].  Myofibrilis are organelles in the shape of a cylinder and are 
composed of the myofilaments of the muscle [1,2].  Myofilaments are the filaments of the 
myofibril and are made up of a thin and a thick filament [3].  The thin and thick filaments of the 
myofilament encompass the actomyosin proteins [3].  The various components of the muscle 
tissue described above are represented in Figure 1.1. 
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Figure 1.1: The various components of muscle as described in the previous pages [3]. 
 
The thick filament of the myofilament is composed of myosin.  Myosin is a motor protein 
that is involved in actin derived muscle contraction and cytokinesis [4].  Myosin is a protein that 
has a functional gobular head and a coiled tail [4].  Myosin heads project from the thick filament 
of myosin toward the thin filament.  The thin filament consists of the proteins actin, 
tropomyosin, and troponin.  These three proteins interact with each other, and the thick filament, 
3 
 
to trigger muscle contraction.   The three major components of the thin filament are depicted in 
Figure 1.1.   
 The myofilament can be presented as a sarcomeric representation of the filaments.  The 
sarcomere is a basic repeating unit of the cell that is composed of the thick and thin filaments of 
the myofilament.  Sarcomeres are the smallest contractile unit of the myofibril [3].  It is the 
sarcomere that gives skeletal and cardiac muscle its striated appearance [3].  The thin and thick 
filaments within the sarcomere interact with each other and slide along one another without 
changing the actual length of the filaments, themselves [3].  A representation of the thin and 
thick filaments in the sarcomere can be found in Figure 1.2. 
 
 
Figure 1.2.  The sarcomere [5]. 
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1.2 Mechanism of Muscle Contraction 
The mechanism by which muscle contraction occurs is an intricate and interconnected 
progression of conformational changes, chemical binding, and protein interactions that 
incorporate all of the anatomy discussed in the previous section of this chapter.  Muscle 
contraction is a process that involves multiple subunits, proteins, and divalent metal ions to 
proceed.   
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Figure 1.3: A representation of the three myosin heads projecting toward the thin filaments of 
actin [6]. 
 
Each equivalent thin filament, consisting of actin, tropomyosin, and troponin, has three 
myosin heads projecting toward it as seen in Figure 1.3 [7].  These projections toward the thin 
filament are termed the myosin-actin crossbridges [7].  Cross striations of myofilaments are 
composed of repeating units called sarcomeres, as discussed in the previous section of this 
chapter [5].  Muscle contraction occurs when the thin filament slides along the thick filament 
causing the sarcomere to shorten [8].  Although the sarcomere, as a whole, shortens, the lengths 
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of the individual filaments do not get shorter, themselves [8].  Figure 1.4 is a good illustration of 
the different stages of muscle contraction as it relates to the sarcomere.  The thick filament of 
myosin is in the center of the sarcomere surrounded and intertwined with the thin filament.  
Figure 1.4 displays the “A-state” as being the most relaxed position of muscle contraction.  The 
sarcomere, in this case, is elongated and relaxed [8].  The “D-state” is the most contracted 
condition of the sarcomere [8].  The “D-state” is the stage in which the sarcomere is at its most 
diminutive point in Figure 1.4.  The “B and C states” in Figure 1.4 represent the intermediate 
steps of muscle contraction and relaxation [8].  As mentioned previously, the sarcomeric 
contractile mechanism is based on the notion that the actual lengths of the thick and thin 
filaments do not change in between the different stages of muscle contraction [8]. 
 
 
Figure 1.4: A sarcomeric observation of muscle contraction. 
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Muscle contraction, itself, is an ATP hydrolysis driven, cyclic interaction of myosin and 
actin [9].  As ATP binds close to the myosin head projections, ATP hydrolysis occurs yielding an 
ADP and Pi molecule [9].  Once the myosin heads bind to actin, Pi is released [9].  After Pi is 
released, the myosin heads propel the actin back toward the tail of the myosin, allowing actin and 
myosin to slide along each other [9]. Once this process is completed, the ADP is released from 
myosin and the head discharges from actin [9].  ATP binds once again and the process continues.  
 There are two ways in which muscle contraction can occur and they are not mutually 
exclusive interactions [10].  The first is a Ca2+ induced muscle contraction.  The ATPase rate of 
myosin is cooperatively triggered by Ca2+ with actin present [10].  Typical ATPase activity in the 
absence of Ca2+ is slow [10].  Ca2+ increases the activity of the ATPase 18-fold [10].  This, in 
turn, decreases the amount of actin necessary for the activity to continue.  The binding of Ca2+ to 
the troponin protein of the thin filament causes a conformational change which leads to muscle 
contraction [10]. 
 The second way in which muscle contraction can occur is when myosin binds directly to 
the muscle.  When myosin heads bind to actin, it augments the ATPase activity eight-fold [10].  
An equivalent troponin-tropomyosin complex is known to bind seven actin monomers [10].  The 
two ways in which muscle contraction is induced via the microanatomical level are 
interconnected mechanisms of action. 
 
 
 
8 
 
1.3 An Introduction to Troponin 
Before the discovery of troponin by Dr. Ebashi in 1963, muscle contraction was known to 
be stimulated by the presence of Ca2+ in the system [11].  However, the way in which Ca2+ 
interacted with the different filaments of the muscle was unidentified.  Following its discovery, 
troponin has been investigated by many spectroscopic and structural techniques and the 
mechanism of action for skeletal and cardiac muscle contraction is better understood.  
Troponin is broken down into three distinct subunits, all of which have their own distinct 
mechanism of action that eventually induces the muscle contraction response discussed 
previously in the chapter.  The three distinct subunits are troponin subunit C, TnC, troponin 
subunit I, TnI, and troponin subunit T, TnT.  The differing troponin subunits exist in multiple 
isoforms for the various types of muscle which include cardiac and skeletal muscle.   
The thin filaments found in representations of the myofilament and the sarcomere are 
composed of actin, tropomyosin, and troponin.  The troponin protein is the starting point of all 
fundamental chemical and micoranatomical action of muscle contraction.  Troponin induces a 
conformational change that induces a muscle contraction response in the thin and thick filaments 
[12].  A ribbon structure of the entire troponin protein is portrayed in Figure 1.5.   
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Figure 1.5: Ribbon Structure of the Entire Troponin Protein [13].  This specific ribbon diagram 
is the cardiac version of the protein.   
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A) Troponin Subunit C (TnC) 
Troponin, as a whole, is an EF-hand motif protein due to the presence of its TnC subunit.  
EF-handed proteins are characterized by a helix-loop-helical secondary structure [14].  It is 
represented by the red in the ribbon diagram in Figure 1.5.  The EF-hands typically occur in 
multiples of two [14].  TnC has two domains, and each domain contains two EF-hand motifs 
[15].  This gives TnC a total of four pairs of EF-hands.  The EF-handed helices are stabilized by 
hydrogen bonding interactions in the loop connecting the pair of helices [15]. Although present 
in troponin, EF-hand motifs are found in many different types of proteins.   
The first conceptual representation of an EF-hand protein was completed by Kretsinger 
and his research group [16].  An EF-hand protein is differentiated by an E-helix and an F-helix 
found in a certain formation which is conveniently located on one’s own hand.  The E-helix is 
represented by the forefinger and the F-helix is represented by the thumb as illustrated in Figure 
1.6 [17].  The calcium ion is found bound in the palm which is in between the thumb and 
forefinger [17].  EF-hand proteins coordinate a calcium ion with pentagonal bypyramidal 
coordination geometry and a coordination number of 7 [18]. 
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Figure 1.6: A representation of an EF-hand protein [19]. 
 
EF-handed proteins can exist as one of two classes of the protein motif.  The first 
characterized EF-hand protein by Kretsinger fit into the class of EF-handed proteins called Ca2+ 
buffers [16].  Ca2+ buffers regulate the interaction between the Ca2+ present in the cell and other 
proteins in the cell [16].  This class of EF-handed proteins can either subtract the amount of Ca2+ 
available to interact with other proteins, or these Ca2+ buffers can distribute the effects of the 
Ca2+ present throughout the entire cell [16].   
TnC fits into the other specific class of EF-handed proteins called Ca2+ sensors [16].  Ca2+ 
sensors allow an increasing concentration of Ca2+ to induce one or more signals [16].  These 
signals are carried by the EF-handed protein and generate biochemical responses that can result 
in different outcomes, including conformational changes [16].   
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Because Troponin subunit C (TnC) is a Ca2+ sensory EF-handed protein, TnC functions 
as the Ca2+ binding subunit of troponin.  TnC binds calcium ions to induce a conformational 
change in troponin subunit I (TnI).  TnC consists of two different domains, the N-domain and the 
C-domain, each having two EF-hands in their structure [13].  The C-domain, or structural 
domain, binds two calcium ions with high affinity, K=107 M-1 [20, 21].  Under physiological 
conditions, Ca2+ displaces Mg2+ from the high affinity sites [21].  Muscle contraction begins 
when the magnesium ion is successfully displaced from these sites.  Mg2+ has been shown to 
possess a weak binding affinity, on the order of K=104 M-1 [21].  It is because of this weak 
binding affinity that calcium can readily displace magnesium from the protein’s divalent metal 
binding sites.   
 
Figure 1.7: Ribbon Structure of Cardiac Troponin C (CTnC).  This representation depicts the 
four EF-handed proteins consisting of two domains joined together by a flexible linker [22]. 
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There are two major isoforms of TnC that exist in the human body.  Skeletal TnC, or 
STnC, is the most prevalent form of TnC found in the body.  It is found in every form of muscle 
tissue excluding cardiac tissue.  Cardiac TnC, or CTnC, is only found in the heart muscle.  There 
are some similarities and differences in the isoforms of the protein.   
The C-domain of TnC is highly homologous in both skeletal and cardiac TnC [20].  The 
biggest difference between the two types of TnC is found in the N-domain, or regulatory domain, 
of TnC.  The N-domain is called the regulatory domain because it is thought to be responsible for 
the regulation of muscle contraction.  Both varieties of the domain bind with the same relative 
affinity, K=105 M-1 [21], but they differ in the number of calcium ions bound to the structure.  In 
STnC, the regulatory domain binds two calcium ions [20].  But, in the CTnC version of the 
protein the N-domain of the protein binds only one calcium ion [20].  Both types of troponin C 
bind two calcium ions at their high-affinity binding sites.  Only STnC binds two calcium ions at 
its low-affinity sites.  In turn, CTnC binds only one calcium ion at a low-affinity site [20].  
Figure 1.7 illustrates the two domains of TnC.  The domain with the two black spheres, 
representing calcium ions, is the structural domain.  The domain with the one black sphere is the 
regulatory domain.  The two globular domains are held together by a flexible linker [22].  The 
presence of only three calcium ions would indicate that Figure 1.7 is a representation of CTnC.  
The binding sites of TnC can be represented as sites I, II, III, and IV, respectively (Figure 1.5).  
CTnC binds calcium ions at sites II, III, and IV [13].  Site II is delegated as the one regulatory 
domain site [13].  A proper depiction of STnC would show a fourth calcium ion bound at site I 
[13, 20].  The reason for the differences in the number of calcium ions bound to the two distinct 
subunits is due to two dissimilarities in amino acid residues.   
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In addition, the affinities with which the regulatory domain and the structural domain 
bind calcium ions is dependent on whether the protein is in complex with other subunits of 
troponin, or if the C subunit is found by itself.  It is thought that when the C subunit is in 
complex with the entire protein or with the troponin I subunit, that the binding affinities for Ca2+ 
increase by an entire order of magnitude [21, 23]. 
 Two aspartic acid residues at the 29 and 31 positions of STnC account for the binding of 
the second calcium ion within the regulatory domain of the protein [20].  These acidic residues 
have negative charges at physiological pH which allow for binding to the divalent metals at this 
extra site.  CTnC, instead, has a leucine residue and an alanine residue present at the 29 and 31 
positions of the protein, repectively [20].  The substitution of acidic amino acid residues for 
nonpolar residues in the skeletal form of the protein allows for coordination to occur between 
those amino acids and the extra calcium ion bound to that form.   
 Dissimilarities also exist in the way in which the two isoforms of TnC mechanistically act 
when binding Ca2+ ions.  STnC switches from a closed to an open conformation upon binding the 
two calcium ions to the regulatory domain [20].  CTnC, however, is thought to undergo minimal 
conformational change upon calcium binding to the N-domain of the protein [20].  The 
differences in conformational change between STnC and CTnC may be attributed to the 
differences in the residues of the protein.   
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B) Troponin Subunit I (TnI) 
TnI is the inhibitory subunit of the troponin protein [13].  The subunit acts as an inhibitor 
by binding the actin-tropomyosin complex to TnC [13].  Binding the complex to the calcium 
binding subunit impedes the progress of muscle contraction.  It is represented by the yellow in 
the ribbon diagram in Figure 1.5.  Once calcium binds to TnC and induces a conformational 
change in the TnI subunit, TnI then binds to tropomyosin [24].  The binding of tropomyosin 
induces formation of the tropomyosin-troponin complex.   
TnI exists in three different isoforms.  Slow skeletal troponin I (ssTnI), fast skeletal 
troponin I (fsTnI), and cardiac troponin I (CTnI) differ in that they are encoded by different 
genes [25].  CTnI has an extended N-terminus, 32 amino acids in length, that has two protein 
kinase A phosphorylation sites which also sets it apart from the ssTnI and fsTnI isoforms of the 
protein [25].   
The functional inhibitory area of cardiac TnI can be broken down into six regions of the 
subunit [22].  The N-terminal region contains an extra extension for the cardiac form of the 
protein [22].  The second region binds the C-domain, or structural domain, of TnC [22].  The 
third region binds to troponin subunit T [22].  The fourth region, or the inhibitory region, of TnI 
can bind actin-tropomyosin to inhibit muscle contraction, or it can bind directly to TnC to reduce 
muscle contraction [22].  The fifth region, or switch region, of TnI binds the regulatory domain, 
or N-domain, of TnC [23].  The switch region can also operate as an activator of the 
conformational changes brought on by the presence of calcium in the system [22].  The final 
region, or the C-terminal region, of TnI binds the actin-tropomyosin complex much like the 
inhibitory region of the protein, but it cannot bind TnC resembling the inhibitory region [22].   
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C) Troponin Subunit T (TnT) 
TnT is the tropomyosin binding subunit of troponin [13].  It is represented by the blue in 
the ribbon diagram of Figure 1.5.  It is the largest subunit of troponin.  TnT binds to actin to 
attach and hold the tropomyosin-troponin complex to the thin filament.  TnT is separated into 
two distinct regions.  The T1 region is responsible for TnT’s interaction with tropomyosin [26].  
The T2 region of TnT is responsible for TnT’s interaction with the TnI and TnC subunits within 
the troponin protein [27].  Other than the subunit’s interaction with other proteins and with other 
subunits within troponin, troponin subunit T’s role in muscle contraction is not well understood.  
The T1 region of the subunit has not been fully characterized.   
 
 
 
 
 
 
 
 
 
 
 
   
Chapter 2: Isothermal Titration Calorimetry 
2.1 An Introduction to Isothermal Titration Calorimetry 
Isothermal titration calorimetry (ITC) is a wonderful instrument to use in investigating 
small molecule and divalent metal binding to proteins such as cardiac TnC.  ITC is a bulk 
thermodynamic technique that measures the heat of a reaction.  ITC can accurately quantify all 
of the thermodymanic properties including: ΔG, ΔH, ΔS, K, and n.   
Binding of a small molecule to a macromolecule generates heat (exothermic event) or 
absorbs heat (endothermic event).  When the macromolecule is saturated with the small molecule 
according to its equilibrium constant, Keq, the heat absorbed or gained will decrease until only 
the background heat of dilution is observed [28].  Fitting this data to a mathematical model 
provides the above thermodynamic parameters.   
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Figure 2.1 Diagram of isothermal titration calorimetry [29]. 
 
Figure 2.1 illustrates the way in which a typical isothermal titration calorimetry 
experiment is run.  A titrant is loaded in the syringe which injects into the reaction cell under 
certain parameters and time intervals.  The syringe is stirred at a constant speed to allow for 
sufficient mixing of the titrant into the analyte.  A reference cell is kept at a constant temperature 
to compare the heat either gained or absorbed by the small molecule binding in the reaction cell.  
The raw data is graphed as a function of µcal/sec vs. time.  If heat is lost when the titrant is 
injected, it will result in a negative peak corresponding to an exothermic heat event.  If heat is 
absorbed during the injection, an endothermic heat event occurs corresponding to a positive peak 
in the raw data.   
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2.2 How Isothermal Titration Calorimetry Functions 
 
Figure 2.2 Diagram of mechanism by which isothermal titration calorimetry works. 
 
 The mechanism by which the isothermal titration calorimeter functions is an intricate 
procedure.  A thermoelectric device is used to measure the difference in temperature between the 
sample cell, or reaction cell, and the reference cell [28].  This measurement is denoted as ∆T1.  A 
second thermoelectric device is used to measure the difference in temperature between the cells 
and the jacket of the isothermal titration calorimeter [28].  This measurement is termed ∆T2.  So, 
as small aliquots of the titrant are added into the reaction cell under the specified parameters, 
heat is either gained or absorbed by the sample cell.  Figure 2.2 illustrates the ITC jacket and 
how the instrument measures the differences in temperature. 
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 The temperature difference between the two cells is held constant by the addition or 
removal of heat by a cell feedback network (CFB) [28].  It is the integral of the power required to 
maintain ∆T1 constant over time that is the function of the heat being observed [28]. 
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2.3 Thermodynamic Parameters Given by ITC   
 Isothermal titration calorimetry, as discussed previously, is unique in that it allows for 
quantification of the different thermodynamic properties of small molecule binding to a protein.  
A binding isotherm is obtained by injecting small aliquots of binding molecule into the analyte 
until saturation occurs.  Each peak represents a reaction that has gone to equilibrium.  The slope 
of an ideal isotherm reveals an accurate determination of the binding constant, or constants, KB 
where M denotes the macromolecule and X denotes the ligand in the following equation [30]:   
 
[ ][ ]B
MX
K
M X
  
Eq. 1 
The inflection point of the binding isotherm discloses the stoichiometry, n, of the binding 
of the titrant with the analyte.  And, the difference in the heats associated with binding and the 
heat associated with the heat of dilution unveils the ∆H value of the binding.   
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Figure 2.3 Typical ITC Raw Data vs. Binding Isotherm Graph [29]. 
 
 
  Figure 2.3 represents a typical ITC binding isotherm with exothermic heat events.  These 
three parameters: ΔH, K, n, unveil the totality of the thermodynamics of the binding using two 
fundamental equations.  The Gibbs’ free energy equations, found below, are the link to the other 
various thermodynamic parameters.   
∆G=∆H-T∆S 
Eq. 2 
∆G=-RTlnK 
Eq. 3 
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Since the temperature is held constant throughout the titration, the Gibbs’ free energy, or 
∆G, can be determined using the binding constant found from the slope of the binding isotherm.  
ΔH can be determined from the difference in heats between the initial point of the binding event 
and the completion of the binding event associated with the titrant and macromolecule.   ∆S, or 
the entropy, can be found once the value of the Gibbs’ free energy is determined.  Once one 
understands all of the thermodynamic contributions of the ligand binding to the macromolecule, 
an understanding of the mechanism and function of binding at the molecular level is better 
understood.   
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2.4 Fitting ITC Data 
 Fitting ITC data can be done using various computer software formats.  The software that 
is available in the laboratory and that is most readily used is Origin™.  Three common fitting 
models, applicable to a wide range of binding phenomena, are available within this software 
package.  These consist of the one set of sites, two sets of sites, and sequential set of sites 
binding models.  In general, there are six important fitting parameters to consider when fitting 
ITC data.  These parameters include K, n, Vo, [M], [X], and Θ and are incorporated into the 
above mathematical models [30].   
K corresponds to the binding constant which can be found by defining the slope of an 
ideal binding isotherm (Figure 2.3).  The stoichiometry value, n, can also be found at the 
inflection point of an ideal binding isotherm and is defined by the molar ratio or ratio of [titrant] 
to [analyte] (Figure 2.3) [30].  The standard active cell volume is denoted as Vo and is unique to 
each brand of calorimeter.  The bulk and un-complexed (free) concentrations of the 
macromolecule present in Vo are defined as Mt and [M], respectively [30].  The bulk and free 
concentrations of ligand found in Vo are defined as Xt and [X], respectively [30].  The fraction of 
sites on the macromolecule occupied by the ligand X is defined by Θ [30].   
All fitting models evaluate the change in heat content, ΔQ(i), from completion of the       
ith – 1 injection to completion of the ith injection for a solution contained in volume Vo [30]. 
( ) ( 1)
( ) ( ) ( 1)2
i ii
i i i
o
Q QdVQ Q Q
V


        
Eq.4 [30] 
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 The second term in the above equation accounts for the displaced volume upon injection 
of titrant. 
 In general, the fitting begins with an initial guess of n single set of sites and two set of 
sites models, only, K, and ΔH [30].  Calculation of ΔQ(i) is done for each injection and a 
comparison is made to the experimental value [30].  The final fit parameters are then improved 
using a standard Marquadt algorithm [30].  This procedure is iterated until no further 
improvements to the fit values occur [30] and the Chi2 value no longer minimizes.  Differences 
between the fitting models arise in the ΔQ(i) expression derived from each binding scenario and 
will be discussed below. 
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A) One Set of Sites Model 
 The equilibrium expression that describes ligand binding to a single set of identical sites 
on a macromolecule is represented by the following equation: 
  1K X
   
Eq. 5 [30] 
 
 Where K is the equilibrium or binding constant, [X] is the free ligand in solution, and Θ 
is the fraction of sites occupied by ligand X as described previously [30].  The total 
concentration of ligand, Xt, can be written as a function of [X] and Mt according to the following 
expression: 
 t tX X n M    
Eq. 6 [30] 
 
 The total heat content, or Q, of the solution contained in Vo (determined relative to zero 
for the un-complexed species) at fractional saturation Θ is the following: 
t oQ n M HV    
Eq. 7 [30] 
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 Combining Eq. 5 and Eq. 6 leaves us with the following equation: 
2 11 0t t
t t t
X X
nM nKM nM
          
Eq. 8 [30] 
 
 Solving Eq. 8 for Θ and plugging the value into Eq. 7 provides us with the following 
equation for Q(i): 
2
( )
41 11 1
2
t o t t t
i
t t t t t
nM HV X X XQ
nM nKM nM nKM nM
                
Eq. 9 [30] 
 
 It is important to note that the floating variables in the above equation are n, K, and ΔH.  
The parameters Xt, Mt, and Vo are known values that are input prior to the fitting procedure [30].   
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B) Two Set of Sites Model 
 The two set of sites binding model is similar to the model above except for the addition 
of the second set of identical sites.  The two sites are non-interacting and may be represented by 
the following expressions: 
  11 11K X
   
Eq. 10 [30] 
  22 21K X
   
Eq. 11 [30] 
 
 The fractional sites Θ1 and Θ2 may be solved independently from Eq. 10 and Eq. 11 and 
are given below [30]. 
1
1
1
[ ]
1 [ ]
tM X K
X K
    
Eq. 12 [30] 
2
2
2
[ ]
1 [ ]
tM X K
X K
    
Eq. 13 [30] 
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 As in the above example, the total concentration of ligand, Xt, can be written as a 
function of [X] and Mt according to the following expression: 
  1 1 2 2( )t tX X M n n      
Eq. 14 [30] 
 
 Substituting Θ1 and Θ2 into Eq. 14 provides the following expression: 
  1 1 1 2 2 2
1 2
[ ] [ ]
1 [ ] 1 [ ]
t t
t t
n H M X K n H M X KX X M
X K X K
         
Eq. 15 [30] 
 
 The total heat content, or Q, of the solution Vo at fractional saturation Θ is the following: 
( ) 1 1 1 2 2 2( )i t oQ M V n H n H       
Eq. 16 [30] 
 
 Substituting Θ1 and Θ2 into Eq. 16 gives us the final expression for Q(i): 
1 1 1 1 2 2
( )
1 2
[ ] [ ]
1 [ ] 1 [ ]
t t
i t o
n H M X K n H M X KQ M V
X K X K
        
Eq. 17 [30] 
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 It is important to note that [X] in the above equation is obtained by Newton’s method 
from Eq. 15 [30].  Once obtained, Q(i) can be solved using the Marquadt least squares procedure 
with initial guesses made for n1, n2, K1, K2, ΔH1, and ΔH2 [30]. 
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C) Sequential Binding Model 
 In a sequential set of sites binding model K1, K2, K3,… are defined relative to the 
progress of the saturation [30]. 
 
  1
MX
K
M X

     
 
  22
MX
K
MX X

      
 
  33 2
MX
K
MX X

 
Eq. 18 [30] 
 This means that one cannot distinguish between the sites that are saturated and that only 
the total number of saturated sites can be determined.  The binding sites are a function of the 
progress of saturation.  The concentrations of all complexed species [MXi] can be expressed in 
terms of [M] [30].  Here we introduce a new parameter, Fi, which is the fraction of the 
macromolecule having i bound ligands [30].  For simplicity, we will consider only a three site 
system which is applicable to our studies. 
2 3
1 1 2 1 2 3
1
1 [ ] [ ] [ ]o
F
K X K K X K K K X
     
Eq. 19 [30] 
1
1 2 3
1 1 2 1 2 3
[ ]
1 [ ] [ ] [ ]
K XF
K X K K X K K K X
     
Eq. 20 [30] 
 
32 
 
2
1 2
2 2 3
1 1 2 1 2 3
[ ]
1 [ ] [ ] [ ]
K K XF
K X K K X K K K X
     
Eq. 21 [30] 
3
1 2 3
3 2 3
1 1 2 1 2 3
[ ]
1 [ ] [ ] [ ]
K K K XF
K X K K X K K K X
     
Eq. 22 [30] 
 
 The total concentration of ligand, Xt, can be written as a function of [X] and Mt according 
to the following expression: 
3
1
[ ]t t i
i
X X M iF

  
 
Eq. 23 [30] 
 
 The fitting procedure is slightly more complex than previously described models.  Free 
ligand concentration [X] must first be obtained.  This is done by the bisection numerical method 
from Eq. 19 through Eq. 23 [30].  Once [X] is obtained, each Fi may be solved for and Q(i) 
calculated from the equation below: 
( ) 1 1 2 1 2 3 1 2 3( [ ] [ ]i t oQ M V F H F H H F H H H          
Eq. 24 [30] 
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2.5 Thermodynamics Discussion 
 Throughout this chapter thermodynamics have been discussed, but an understanding of 
what the different thermodynamic parameters truly mean has not been mentioned.  The Gibbs’ 
free energy equation, Eq. 2 and Eq. 3, reveal quite a bit of information regarding a 
macromolecule’s interaction with the titrant of interest using ITC.   
 Gibbs’ free energy, or ΔG, is important in understanding the favorability of a reaction.  A 
negative ΔG value corresponds to a favorable chemical reaction.  This means that work is not 
required for the reaction to go forward.  The reaction will proceed on its own regardless of an 
input of work.  A positive ΔG value corresponds to a non-favorable chemical reaction.  Work 
must be applied from the surroundings to force the reaction to proceed in the forward direction.  
Negative Gibbs’ free energy values are termed exergonic and positive Gibbs’ free energy values 
are termed endergonic.  Gibbs’ free energy is a function of enthalpy, entropy, and equilibrium 
constant values, as defined in Eq. 2 and Eq. 3. 
 The binding constant, or K, value gives insight into the tightness of binding associated 
with the ligand to the macromolecule of interest.  Positive values for lnK result in negative 
values toward Gibbs’ free energy.  So the larger K value, corresponds to the more negative ΔG 
value.  This would indicate a tighter binding.  If the binding constant is greater than 1, it will 
result in a favorable reaction.  If the binding constant is less than 1, it will result in a non-
favorable reaction. 
 Enthalpy, or ΔH, is a function of the heat that is resultant of the titration conducted using 
isothermal titration calorimetry.  If heat is released upon small molecule binding to the 
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macromolecule, there is an exothermic heat event that occurs.  Exothermic heat events result in a 
negative value for ΔH.  If heat is absorbed from the surroundings during a titration event, there is 
an endothermic heat event that occurs.  Endothermic heat events result in a positive value for 
ΔH.  Enthalpy will contribute to the spontaneity of the reaction if the titration results in an 
exothermic heat event.  Conversely, enthalpy will contribute to the non-spontaneity of a reaction 
if it is an endothermic heat event.   
 Enthalpy is a function of contributions from hydrogen bonding, van der Waals forces, 
electrostatic interactions, π/π interactions, and water-related specific hydrogen bonding 
interactions [31, 32].  Hydrogen bonding contributions toward enthalpy stem from optimal 
positioning of hydrogen bonding donors and acceptors [31].  This is necessary to balance the loss 
of enthalpy due to desolvation of the polar group [32].  A multitude of changes in bond energy 
occur as a result of breakage and formation of hydrogen bonds, but there must be an amount of 
correctly positioned hydrogen bonding that occurs to offset the desolvation enthalpies.  Van der 
Waals attractions rely on the distance of binding interactions.  If the two interacting molecules 
are too close, there will be repulsion.  If the molecules are too far apart, the affinity will be too 
weak for sufficient interaction to occur [32].  Electrostatic interactions can be attributed to ionic 
interactions of charged species.  Formation of water hydrogen bonds from a ligand to water 
molecules deep in the active site can result in a large contribution to enthalpy [32].  This 
contribution to enthalpy can offset the loss of enthalpy that occurs when water is removed from 
the active site [32]. 
 Entropy, or ΔS, is a bit more complicated.  A positive entropy value will contribute to the 
spontaneity of a chemical reaction.  However, negative entropic values will contribute to the 
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non-spontaneity of a chemical reaction.  Most learn entropy as being a function of the disorder or 
energy dispersal created from a reaction, but entropy can be attributed to a lot of different 
interactions that transpire when binding occurs.  Entropy can be described as a dependence on 
the dispersion of energy and the distribution of energy among a large number of molecular 
motions [33].  Equation 25 shows how entropy is a quantity of the unidirectional flow of thermal 
energy since Δq is the thermal heat and T is the temperature in the equation below [33]. 
ΔS ≥ Δq/T 
Eq. 25 
 Entropy change is best described as a measure of energy’s dispersion at a specific and 
defined temperature [33].  It can also be defined as an energy dispersal involving molecules in 
microstates [33]. 
Entropic contributions toward binding stem from hydrophobic interactions.  Hydrophobic 
interactions can be understood by assuming that non-polar groups tend to coalesce and minimize 
interaction with solvent [31].  This comes from an increase in solvent entropy from the 
hydrophobic groups being buried and the release of water upon binding [34].  This positive 
entropic event is partially offset by an ordering of the ligand in the active site [34].  This 
hydrophobic interaction will result in a slight endothermic heat event and large positive entropy.  
Entropic contributions are also characteristic of miniscule loss of conformational degrees of 
freedom [31].   
 
   
Chapter 3: Familial Hypertrophic Cardiomyopathy 
and Project Importance 
3.1 An Introduction to Familial Hypertrophic Cardiomyopathy 
Familial hypertrophic cardiomyopathy, FHCM, is a genetic disorder characterized by an 
abnormal growth in the wall of the left ventricle of the heart.  It causes an abnormal muscle 
contraction response in people afflicted with the genetic disorder.  Multiple mutations found in 
cardiac troponin have been linked to this disease.  FHCM transpires in roughly 1 out of every 
500 people making it one of the most frequently occurring genetic cardiac disorders [35].  
Roughly 5-10% of people afflicted with this disorder suffer fatal cardiac arrest at some point in 
their lifetime [36].  It is the leading cause of sudden death in young athletes [37].  One of the 
more infamous cases of FHCM occurred when Hank Gathers, a Loyola Marymount basketball 
player, collapsed on the court during a tournament game in 1990 and died shortly thereafter.  It 
was later found that he was afflicted with this disorder after the autopsy was conducted.  The 
mechanism of inheritance for familial hypertrophic cardiomyopathy is not completely 
understood.  It is thought to be an autosomal dominant trait, but it has variable penetrance to the 
next generation [38].  
 Clinical studies have shown that variance of the disease’s manifestation, even within the 
same family, is a common occurrence.  Multiple symptoms are characteristic of FHCM.  People 
afflicted with the disorder can be asymptomatic almost their entire lives, but detection usually 
occurs in the first few years in adolescence [39].  
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3.2 Bepridil and Other Calcium Sensitizing Drugs 
Bepridil can be found throughout the literature as a possible treatment for familial 
hypertrophic cardiomyopathy.  A chemical representation of Bepridil can be found in Figure 3.1 
which depicts Bepridil in complex with HCl.  The HCl is present to ensure the nitrogen atoms 
found in the Bepridil molecule are protonated.  Protonating the nitrogen atoms cause the drug to 
be more soluble and prevent oxidation.  Bepridil has been shown to increase CTnC’s affinity for 
binding Ca2+ in vitro [40].  Hence, Bepridil and drugs like it have been termed: “calcium 
sensitizers” [40].  It has also been shown to increase the activity of the actomyosin ATPase rate 
in vitro [40].   People afflicted with FHCM may be able to take this “calcium sensitizing” drug, 
or others like it, to increase CTnC’s affinity for Ca2+ as well as the actomyosin ATPase activity 
which should induce normal, or increased muscle contraction response from the drug therapy.   
But, Bepridil is not currently used as a treatment for the disorder in the United States because of 
dangerous side effects associated with the drug therapy. 
 
N O
N
. HCl
 
Figure 3.1 A chemical respresentation of Bepridil • HCl 
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There are some issues associated with Bepridil’s use in the treatment of FHCM.  Some of 
the more dangerous side effects associated with treatment using Bepridil include: acute 
myocardial infarction, worsened heart failure, and sudden death [41].  Some of the less 
dangerous, yet still problematic, side effects include: gastrointestinal problems and psychiatric 
issues [41].  These drastic side effects are some of the reasons that the drug is not available to 
people in the United States of America and why more effective yet safe treatments are necessary 
in the treatment of the disorder. 
 Even though there are definite dangerous side effects accompanied with a treatment using 
Bepridil, an investigation of the thermodynamics of binding to troponin subunit C may reveal a 
better understanding of the mechanism by which Bepridil binds to TnC.  This can be essential in 
determining whether a treatment using other “calcium sensitizing” drugs is a viable possibility 
for treatment of this disorder. 
Bepridil allows troponin to be more sensitive to the presence of calcium which induces 
cardiac muscle contraction [40].  The drug binds weakly to troponin in the absence of Ca2+.  
Bepridil is known to bind tightly in 3 equivalents to the Ca2+ saturated version of the TnC subunit 
of troponin, when the subunit is not in complex with the rest of the troponin protein, as seen in 
Figure 3.2 [40].  When the subunit is combined with the entire complex of troponin (TnI, TnT, 
TnC), only one equivalent of Bepridil is found to be bound to the entire protein. 
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Figure 3.2 A stereo representation of 3 equivalents of Bepridil bound to a single CTnC [42]. 
 
 The mechanism by which Bepridil binds to troponin has been hypothesized by the Li 
group, but the thermodynamic understanding of binding is still not completely characterized.  
The Li group has found that Bepridil stabilizes the fully open N-lobe of Cardiac TnC and a 
closing of the N-lobe is associated with the release of Ca2+ from that binding site [42].  So, 
Bepridil holding the N-lobe of CTnC open allows for the protein to be more sensitive to the 
presence of calcium.  Bepridil’s binding to the protein results in a rearrangement of the hydrogen 
bonding within the regulatory domain.  Because the drug is known to bind three equivalents to 
the CTnC subunit, the binding of the extra two drug molecules may inhibit the binding of TnI to 
the subunit. 
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3.3 Project Importance 
Considering Familial Hypertrophic Cardiomyopathy is a significant problem and affects a 
considerable number of the population, the way in which this disorder can be or should be 
treated is still debatable.  We hope to uncover the possibility of using a “calcium sensitizing” 
drug as a treatment of this disease as opposed to other options presented in the literature.   
The underlying goal of this research project is to determine thermodynamic binding 
properties of Bepridil to troponin using isothermal titration calorimetry.  Understanding the 
thermodynamic properties with which a drug interacts with a protein may help reveal the 
mechanism of action by which the drug operates.  We will be able to see how calcium sensitizing 
drugs interact with troponin and determine their practicality in drug design for patients afflicted 
with familial hypertrophic cardiomyopathies.  Appreciation of the mechanism by which the drug 
operates is a crucial point in understanding the way in which it is best to approach treating this 
disease.   
A basic understanding of the thermodynamic binding properties of this drug to the 
protein can help to explain the interactions of the drug with the protein in terms of hydrophobic 
interactions, electrostatic interactions, hydrogen bonding, conformational changes, and other 
mechanistic properties [31].   
Historically, drug design began by investigating the binding constant, Kd, to determine 
the tightness of binding associated with the drug and the target site of action.  However, drug 
targets with high Kd’s do not necessarily equate to useful drugs.  ITC has given the researcher the 
opportunity to look at other thermodynamic properties of the drug’s interaction with a protein.  
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∆G reveals the tightness of binding of the drug to the protein.  A largely negative ∆G reveals a 
spontaneous reaction in which the drug binds tightly to the protein.  When determining how this 
calcium sensitizing drug operates, it will be of importance to note if the reaction is entropically 
driven, enthalpically driven, or driven by a combination of both parameters.  Enthalpy measured 
from the isothermal titration calorimeter reveals the strength of Bepridil’s interaction with the 
protein.  A reaction is enthalpically driven when ∆H is largely negative.  This contribution 
toward ∆H is characteristic of van der Waals interactions, hydrogen bonding properties, 
electrostatics and π/π interactions [31]. 
Reactions that are largely entropically driven reveal a largely positive T∆S along with a 
positive ΔH.  Entropically driven reactions are primarily the result of hydrophobic interactions.  
A reaction may be characteristic of a hydrophobic interaction if ∆H is small and ∆S values are 
large and positive.  The solvent water effect around a nonpolar solute can cause this interaction.  
The increase in entropy stems from the liberation of ordered water molecules around the apolar 
surface.  It also may reflect the rigidity of the interaction of the drug with the target protein, since 
there will be no loss of conformational degrees of freedom upon binding to the protein.  
Traditional drug optimization was largely entropically driven and designed with restricted 
conformations to fit in a drug pocket with added hydrophobicity.  This can be a problem because 
the drug may not work for different mutations associated with familial hypertrophic 
cardiomyopathies [31].  Therefore, optimizing enthalpically driven binding may be more 
advantageous in drug design. 
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3.4 Project Objectives 
As mentioned previously, drugs used in the treatment of FHCM, such as Bepridil, act as 
calcium sensitizing agents.  Prior to embarking on a thermodynamic investigation of Bepridil 
binding to troponin, it is important to obtain an understanding of the thermodynamics of calcium 
binding to the protein.  Therefore, the objectives of this project are to: 
 Obtain the thermodynamics of calcium and magnesium binding to bovine cardiac TnC, 
the calcium binding subunit of the troponin complex. 
 Obtain the thermodynamics of calcium binding to the apo form of human cardiac TnC. 
 Study the thermodynamics of Bepridil binding to the protein in the presence of calcium.  
The C subunit of cardiac troponin, as opposed to the entire complex of the protein, was 
used due to the simplicity of the system.  It also establishes a baseline of thermodynamic 
parameters for the protein.   
 
 
 
 
 
 
 
   
Chapter 4: Thermodynamic Results 
4.1 Sample Preparation 
Thermodynamic studies involving bovine cardiac troponin C (BvCTnC) utilized protein 
that was previously isolated from bovine heart muscle.  The protein was generously donated by 
Dr. Chalovich’s group at the Brody School of Medicine.  Later thermodynamic studies focused 
on the human form of cardiac troponin (HCTnC).  This protein was over-expressed in bacteria 
cells and purified according to the following procedure obtained from the Chalovich laboratory.   
An LB Agar plate containing 100 μg/mL was streaked with bacteria from a cell stock 
from the Chalovich group and placed in a 37°C incubator overnight to facilitate the growth of 
single colony cells.   XL1Blue competent cells were used.  A starter culture was prepared by 
inoculating 1 liter of sterilized LB broth containing 100 μg/mL of ampicillin with a single colony 
chosen from the agar plate.  The starter culture was allowed to shake overnight at a temperature 
of 37°C and a speed of 225 rpm.   The following morning, 100 mL of starter culture was 
dispersed into four Fernbach flasks containing LB broth and ampicillin (100 μg/L) and allowed 
to shake at 37°C for roughly three and a half hours.  The optical density (600 nm) was taken at 
variable time intervals to ensure a desirable reading of roughly 1.50 A.  The sample was then 
placed into a centrifuge and spun at 4,000 rpm for 30 minutes at 4°C.  The supernatant was 
poured off and the cell pellet was collected.  This was repeated until all of the growth had been 
spun down.   
The next step in the growth and purification process required resuspending the cell pellet 
in a resuspension buffer, and lysing the cells.  The resuspension buffer of 1 mM EDTA and 50 
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mM Tris/HCl at a pH=8.0 was used to resuspend the precipitate collected from the centrifuge 
into solution.  Roughly 30 mL of the resuspension pellet requires 86 mg of Protease Cocktail 
Inhibitor, 0.4 mL of DMSO, 1.6 mL of H2O, and 40 mg of Deoxycholate.  These compounds, 
especially the protease cocktail inhibitor, function to preserve cellular protein composition 
during lysis [42].  The resulting suspension was then placed in a French Press at 2000-2500 psi 
to lyse the cells.  This procedure was repeated, roughly 3 times, until an entirely dark and viscous 
liquid was retrieved from the French Press.  All of this was done with ice present to prevent 
degrading of the sample.  The French Press cell was also cooled in an ice bath before each use to 
ensure that the sample was maintained at a reasonably cold temperature.  After lysing the cells 
the sample was placed in a centrifuge for 30 minutes at 18,000 rpm and 4°C.  The supernatant 
was collected and the volume was measured.  CaCl2 and MgCl2 were added to the sample to 
make its concentrations equivalent to 5 mM and 1 mM, respectively.  Next, a 60% ammonium 
sulfate precipitation was conducted in order to clarify the protein sample and remove any cellular 
debris and unwanted protein.  The sample was then centrifuged at 18,000 rpm for 20 minutes at 
4°C, again.  The supernatant was, again, collected and the final process of purification began. 
A 30 mL phenyl sepharose column was set up and equilibrated with 1 M NaCl, 1 mM 
CaCl2, and 50 mM Tris/HCl at a pH=8.0.  The supernatant sample described in the previous 
paragraph was loaded onto the column in a controlled room temperature of 4°C and the protein 
was allowed to sit on the column overnight to ensure sufficient binding to the column.  Two 
consecutive washings of the sample and the column occurred.  The sample was first washed with 
500 mL of 1 M NaCl, 1 mM CaCl2, and 50 mM Tris/HCl at a pH=8.0.  The second wash 
included 500 mL of 1 M NaCl, 0.2 mM CaCl2, and 50 mM Tris/HCl at a pH=8.0.  The washes 
are performed to remove impurities and to tightly bind the protein to the column to prepare for 
45 
 
the elution process.  The protein was eluted with 400 mL of 5 mM EDTA and 20 mM Tris/HCl 
at a pH=8.0.  The protein was collected using a fraction collector and the progress of protein 
elution was tested using a Bradford assay at variable intervals to check for the presence of 
protein.  Fractions were collected at roughly 5 mL intervals using a fraction collector.  The 
concentrations of the various fractions that tested positive using the Bradford assay were verified 
using a NanoDrop 2000C spectrophotometer.  The concentration of the protein was calculated 
using an extinction coefficient of 4595 M-1 [44].  The samples were then tested for purity using 
gel electrophoresis.   
Figure 4.1 shows a typical SDS-Page gel after it has been stained EZ Run Protein Gel 
Staining Solution from Fisher Scientific and rinsed three times with 200 mL of 18 MΩ water.  
The gel shows that HCTnC is present with little to no impurities present in the sample.  The 
molecular marker to the left is a ladder that indicates increasing molecular weights as one 
observes from the bottom to the top of the gel.  The arrows to the left of the gel denote the 
molecular weights that correlate with the major bands in the marker.  Arrows A-G denote 
different fractions collected from the fraction collector during the elution process.  All of the 
bands (A-G) fall in between the 20,040 Da. and 14,313 Da. marks.  Since the bands fall in 
between the last band of the run and the second to last band, the bands correlate with the 
literature value of the molecular weight of HCTnC which is roughly 18,427 g/mol [22].  HCTnC 
is most prevalent in bands B through D which is why the bands in these lanes are the darkest.     
 
 
46 
 
66,409 Da
26,625 Da
20,040 Da
14,313 Da
Protein Molecular 
Weight Marker
A B C D E F G
 
Figure 4.1. A picture of a successful gel electrophoresis using HCTnC and a molecular marker.  
Lanes A-G represent fractions 9-10, 11-13, 14-16, 17-19, 20-22, 23-25, and 26-28 respectively.  
Broad range molecular markers from Jule, Inc. were used in all gel electrophoresis. 
 
After an electrophoresis is run and a positive result is found from the gel, we then 
dialyzed the protein against the standard buffer concentration of the protein, 10 mM MES, 50 
mM KCl, at a pH=7.0.  The dialysis was done with one liter of dialysis buffer 4 times with 2 
hour spacing between the first 3, and the last dialysis was run overnight.  For the Bepridil runs, a 
slight modification is made to the dialysis procedure.  We dialyzed against 5% ethanol to ensure 
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compatibility with the titrant.  The ethanol is present to ensure Bepridil is in solution.  The 
dialysis of the protein sample was also done at a pH of 5.7 due to Bepridil’s insolubility at a pH 
higher than this value.  CaCl2 is also present in 10 mM concentration to make sure calcium is 
fully bound to the protein when doing titrations involving Bepridil with the protein.   
For titrations involving the apo form of the protein, Ca2+ must be removed from the 
protein to ensure decent results from the isothermal titration calorimeter.  In order to remove 
calcium from the protein, we placed Chelex®100 into a vial containing the protein and mixed it 
overnight at 4°C.  This allowed for ample time for removal of calcium from the high affinity and 
low affinity binding sites of the protein.  We also ran our dialysis buffer through a Chelex®100 
column to ensure removal of trace amounts of calcium. 
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4.2 Isothermal Titration Calorimetry Conditions 
All of our isothermal titration calorimetry experiments were conducted under the same 
conditions, with a slight exception for Bepridil titrations, for consistency and reproducibility 
throughout the research and for comparisons to other studies in the literature.  The buffer 
concentrations of all titrations were 10 mM MES and 50 mM KCl at a pH=7.0.   
 
 
Figure 4.2. A chemical representation of MES (2-(N-morpholino) ethane sulfonic acid). 
 
 MES (2-(N-morpholino) ethane sulfonic acid) is used because it has minimal salt effects 
in terms of ionic strength, has little coordinating effect with metal ions, and keeps the ionic 
strength at a constant.  Considering hard-soft acid-base (HSAB) theory, magnesium and calcium 
ions are hard acids and the sulfite of MES is a soft base.  Since hard-hard interactions are more 
favorable than hard-soft interactions, the metal ions of calcium and magnesium are much more 
likely to coordinate with the hard base areas of the protein than with the soft base sulfonate of the 
MES buffer.  MES buffer was also used to mimic conditions used in other studies concerning the 
protein.  KCl is used as a buffer to mimic salt concentrations in the body.   
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 ITC experiments were set up by delivering 8 μL injections of titrant with 250 second 
spacing between injections.  The only exception being the initial injection point which delivers 
only 2 μL and only has a 120 second spacing before the second titration is delivered.  The 
spacing between injections allows for the system to re-equilibrate and reach baseline equilibrium 
before performing the next injection.  The calorimeter was held at a constant temperature of 
25OC.  Lastly, the stirring speed of the instrument was kept at 307 rpm.  Stirring allows for 
adequate mixing of the titrant with our protein.   
 Titrations involving Bepridil posed a bit of a problem in regards to solubility of the 
“calcium sensitizing” drug.  In order to get a decent concentration of Bepridil present to execute 
successful titrations, a pH of 5.7 is necessary and 5% ethanol must be present in the sample.  
Consequentially, getting Bepridil into solution requires one to first dissolve Bepridil in 100% 
ethanol before diluting the sample to the appropriate buffer conditions.  So, buffer conditions 
were mimicked by adding KCl and MES buffers to ensure its consistency with the protein buffer 
conditions.  Final buffer concentrations with Bepridil present were 50 mM KCl, 10 mM MES, 
5% Ethanol, 10 mM CaCl2 and a pH of 5.7.  The buffer conditions for BvCTnC experiments 
differ slightly in terms of percentage of ethanol present.  The protein was dialyzed under the 
same buffer conditions as described in the previous section of this chapter.  The CaCl2 is present 
so that the divalent metal is occupying all three binding sites in cardiac troponin subunit C for 
experiments where this is necessary. 
 
 
50 
 
4.3 Ca2+ and Mg2+ Binding to BvCTnC  
The initial focus of our research was to investigate the thermodynamic binding properties 
of various divalent metals to the apo form of the Troponin C subunit of the cardiac muscle 
protein.  Binding data and thermodynamic investigations of cardiac troponin C exist using 
fluorescence and microcalorimetric titration studies which serve as good comparisons to our 
isothermal titration calorimetry studies [21, 45-47]. 
The Yamada group has done extensive work investigating the thermodynamics of 
calcium and magnesium ions binding to the apo form of TnC [45-47].  They began their work 
using a modified Rhesca conduction microcalorimeter [45].  These experiments were conducted 
with STnC from rabbit in buffers which were different from ours: a greater concentration of KCl 
(100 mM), Tris-HCl (25 mM), and a greater pH = 8.83 [45].  All of these experiments were 
conducted at a lower temperature of 10°C.  These preliminary experiments were done with 
MgCl2 (1 mM) present [45].  The high pH was due to proton exchanges of TnC upon Ca2+ 
binding [45].  They were able to reduce this proton exchange problem to a negligible level with a 
high pH [45].  This paper found binding constants on the order of 107 M-1 for one high affinity 
binding site and 105 M-1 for the other high affinity binding site [45].  It also showed an enthalpic 
contribution of ΔH = -2.4 kcal/mol and an entropic contribution of TΔS = 6.67 kcal/mol toward 
the one high affinity site [45].  The study also showed an enthalpic contribution of ΔH = -6.13 
kcal/mol and an entropic contribution of TΔS = .351 kcal/mol to the other high affinity site [45]. 
The next set of experiments by the Yamada group was done using a batch 
microcalorimeter [46].  These experiments were performed using BvCTnC in 0.1 M KCl, 20 mM 
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Pipes-NaOH and at a pH of 7.0 [46].  The experiments were conducted at varying temperatures 
including: 5°C, 15°C, and 25°C [46].  These experiments show lower binding affinity constants 
as the temperature is increased to 25°C.  The binding affinity in the presence of Mg2+ at 25°C 
was K = 106 M-1 and the enthalpic contribution was ΔH = -4.76 kcal/mol [46].  In both of these 
studies they were never able to discern the low-affinity binding site in TnC.  They mentioned 
that if heat were generated, it was undetectably small [46]. 
We initiated our research with the bovine form of CTnC.  This allowed us to have a 
reference for titrations when conducting these same experiments with the human form of the 
protein.  As the data will show, our values confirmed a positive correlation with the literature in 
regards to binding constant values associated with the protein.  
 Most data found in this chapter is an average of multiple data sets.  Throughout the 
chapter, one will notice that a sole example is given of raw data and a binding isotherm of 
interest at that point in the chapter.  A data table follows each ITC raw data and binding isotherm 
figure which averages data from the multiple data sets.  The data tables come from multiple data 
sets.  The raw data and binding isotherm presented is a typical data set from a repeat of 
experiments.  The other raw data and binding isotherms from which the data is compiled can be 
found in an appendix at the end of the thesis.   
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A) Ca2+ Binding to BvCTnC 
A representative isotherm of CaCl2 (0.6 mM) titrated into the apo form of BvCTnC (10 
μM) is shown in Figure 4.3.  The first heat event is highly exothermic and occurs at a molar ratio 
of 2 calcium ions per protein molecule.  This event represents calcium ions binding to the two 
high affinity divalent metal ion sites in the structural domain of BvCTnC.  The data may be 
interpreted as two calcium ions binding with the same binding constant, K, and enthalpy value, 
ΔH.  The data may also be interpreted as two calcium ions binding with positive cooperativity 
where binding of the first calcium ion increases the binding affinity for the second calcium ion.  
In the latter model, one will not be able to separate the two sets of binding parameters since 
binding of the first metal will be followed by binding of the second metal with increased affinity.  
Therefore, the heat observed in an injection will be a summation of ΔH1 and ΔH2. 
The second binding event occurs at a molar ratio of three and refers to the binding of the 
third and final Ca2+ to the low affinity site in the regulatory domain of BvCTnC.  The data shows 
that the binding event is endothermic.  The slopes of both the exothermic and endothermic heat 
events are characteristic of the binding constant, K, as described in Chapter 3 of this thesis.  It is 
clear from the data that the first event has a sharper slope which is indicative of tightly bound 
calcium ions while the subsequent endothermic heat event has a gentler slope and is indicative of 
a more weakly bound calcium ion. 
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Figure 4.3.  A titration of Ca2+ (0.6 mM) into apo BvCTnC (10 µM).  Experiments were 
conducted at room temperature (25oC).  All protein and metal solutions were in 10 mM MES and 
50 mM KCl at pH=7.0 buffer conditions.  Aliquots were delivered in 8 µL injections with a 
spacing of 250 s in between each injection.  The stirring speed for the ITC was 307 rpm.  This 
data set was fit to a “two set of sites” binding model. 
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I. Analysis of Fit Parameters 
Two different models were used to fit the data shown in Figure 4.3.  These included the 
“two set of sites” and “sequential set of sites” models and were previously discussed in chapter 3 
of this thesis.  In short, the “two set of sites model” considers the saturation of two independent 
sites within the macromolecule.  Each individual site is represented by the fitting parameters n, 
K, and ΔH.  The “sequential set of sites” model assumes a fixed sequence of binding where the 
first ligand always binds to site 1, the second ligand binds to site 2 and so on.  The number of 
sites must, therefore, always be integral and are defined by the operator.  The fit parameters are 
Kn and ΔHn for each site where n refers to the first, second, or third ligands, etc.  It is important 
to note that both models converge when the binding affinities of both sites differ by the several 
factors [30].  ITC fitting data for both models have been compiled in Table 4.1. 
Fitting data to a “two set of identical sites” model and allowing all parameters to float 
resulted in values of n1, K1, ΔH1, n2, K2, and ΔH2 (Table 4.1).  The n1 value of 2.33 (± 0.03) 
represents the binding of two calcium ions to identical sites with K1 and ΔH1 values of 1.3 (± 0.1) 
x 106 and -9.31 (± 0.04) x 103 kcal/mol respectively.  The n2 value of 1.28 (± 0.05) indicates that 
only one calcium ion is bound to the second site on the protein and represents calcium binding to 
the lower affinity regulatory domain of BvCTnC.  This site has a calcium binding affinity, K2, of 
6 (± 1) x 104 and ΔH2 of 1.43 (± 0.03) x 104 kcal/mol.  It is important to note that the binding 
constants obtained in the “two set of sites” model agree nicely with values reported in the 
literature (Table 4.2) [21, 45-47].  The binding constants for the higher affinity sites differ by a 
factor of 2, while the lower affinity binding constants agree quite closely.  The differences in 
binding constants may stem from differing buffer conditions and issues with ionic strength.  It 
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also may be a function of the pH that the experiment was conducted under.  The Yamada group 
ran their experiments under higher buffer conditions.  Lastly, in the Yamada paper when the 
temperature was increased to 25°C, the binding constant got significantly smaller [46].  The 
binding constants (106 M-1) using their calorimetric methods approached our values reported in 
this thesis when they conducted their experiments at 25°C [46]. 
 
 
 
 
 
 
 
 
 
 
 
 
56 
 
Table 4.1.  Comparison of thermodynamic fitting parameters obtained for Ca2+ titrated into apo 
BvCTnC using the “two set of sites” and “sequential set of sites” binding models. 
“Two Set of Sites” Binding Model “Sequential Set of Sites” Binding Model 
High affinity binding sites representing two calcium ions. 
n1 2.33 (± 0.03) -- -- 
K1 1.3 (± 0.1) x 106 K1=K2a 6 (± 1) x 105 
ΔH1 -9.31 (± 0.04) x 103 ΔH1=ΔH2b -9.72 (± 0.248) 
Low affinity binding site representing one calcium ion. 
n2 1.28 (± 0.05) -- -- 
K2 6 (± 1) x 104 K3 3.7 (± 0.2) x 104 
ΔH2 1.43 (± 0.03) x 104 ΔH3 1.7 (± 0.2) x 104 
Chi2 1.5 x 104 Chi2 1.9 x 104 
 
a. Both K1 and K2 were constrained to equal each other during the fitting procedure. 
b. Both ΔH1 and ΔH2 were constrained to equal each other during the fitting procedure. 
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 Fitting the data to a “sequential set of sites” model and allowing all parameters K1, K2, 
K3, ΔH1, ΔH2, and ΔH3 to float did not yield a suitable fit because the model failed to converge 
on a unique set of binding parameters.  It was only when K1 and K2, and ΔH1 and ΔH2 were 
constrained equal to each other that the curve was satisfactorily fit to the binding isotherm.  
Comparing K values for the high affinity binding site from both models reveals very similar 
affinities with the “sequential binding sites” model differing only by a factor of 2.  The K values 
obtained for the lower affinity site also followed a similar trend differing only by a factor of 1.6.  
The ΔH values obtained from both models were in better agreement (Table 4.1). 
 The largest discrepancy between the two models stems from the quality of fits.  The Chi2 
value for the “two set of sites” model is smaller than the Chi2 value obtained in the “sequential 
set of sites” model (Table 4.1).  As discussed in chapter 3, the Chi2 value allows one to compare 
the quality of fit.  A lower Chi2 indicates a better fit to the binding isotherm and this suggests that 
the “two set of sits” model provides a better and more reliable fit to the data.   
 The poor fit of the “sequential set of sites” model is evident in Figure 4.4.  The fit line 
fails to pass through the initial point in the isotherm and nearly bypasses several points in the 
endothermic portion of the curve.  The quality of the fit generated by the “sequential set of sites” 
model may be due to not knowing the precise concentration of the calcium and the protein.  Non-
integer n values obtained in the “two set of sites” model may be an indication that the 
concentrations were not precise.  Furthermore, the two additional fitting parameters in the “two 
set of sites” model may provide more variability to allow for a better fit to the isotherm.  Because 
of the higher quality of fit obtained with the “two set of sites” model, this data will be used in 
later discussions. 
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Figure 4.4. The data represents the same titration as seen in Figure 4.3.  The data was fit to a 
“sequential set of sites” model. 
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II. Discussion of Thermodynamic Parameters 
A full set of thermodynamic parameters describing calcium binding to apo BvCTnC were 
obtained from the “two set of sites” fit parameters and are reported in Table 4.2.  The Gibbs’ 
free energy of a system may be calculated from the binding constant, K, of the reaction 
according to the following equation: 
ΔG = -RT lnK 
Eq. 26 
 The entropy, ΔS, of the binding reaction may then be obtained from ΔG and ΔH 
according to the Gibbs’ free energy equation given below: 
ΔG = ΔH – TΔS 
Eq. 27 
 Binding of calcium ions to the two high affinity sites in the protein occur with a large 
negative ΔG1 (-8.3 (± 0.1) kcal/mol).  Negative Gibbs’ free energy values indicate favorable 
reactions that do not require additional input of energy to continue to completion.  Binding 
calcium to the two high affinity sites of BvCTnC has a ΔH value of -9.31 (± 0.04) kcal/mol.  
Calcium binding to EDTA under similar conditions results in a ΔH value of -4.1 kcal/mol [48].  
It is interesting to note that the ΔH1 obtained in this study is roughly two times the EDTA value 
and represents the heat exchanged when two calcium ions bind to the protein.  The entropy 
observed for the high affinity sites is negative as well.  This corresponds to a TΔS value of -1.0 
(± 0.1) kcal/mol and is not entropically favored.  The binding of calcium ions to the two high 
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affinity binding sites is, therefore, enthalpically driven.  The –TΔS value may stem from the loss 
of conformational degrees of freedom of the amino acid ligands upon calcium ion binding.  
Furthermore, the high affinity calcium sites are required for the structural stability of the protein.  
This negative entropy may also be a consequence of the rigidity imposed on the protein by 
calcium ions binding to these two sites [40]. 
 The second binding event represents an interesting development in regards to calcium 
binding to the regulatory domain of BvCTnC.  The ΔG2 value of -6.5 (± 0.1) kcal/mol indicates 
that the binding of calcium to the regulatory domain is still favorable.  However, the reaction is 
not driven by the same thermodynamic parameters as previously reported for the structural 
domain’s two high affinity sites.  ΔH2 is largely positive, 14.30 (± 0.03) kcal/mol, and 
enthalpically disfavored.  This means that the driving force for the reaction is entropic in nature 
with a TΔS of 20.8 (± 0.2) kcal/mol.  This is interesting because the opening of a hydrophobic 
area in the protein should be entropically disfavored.  The entropy reported is a total contribution 
toward entropy, so another force must override this entropically disfavorable process.  There 
must be some sort of conformational flexibility that is occurring that is much greater than the 
disfavored entropic contribution mentioned previously.  ITC studies involving calmodulin, a 
protein of similar structure and binding characteristics, showed a similar thermodynamic profile 
[49]. 
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Table 4.2. Thermodynamic Properties of Ca2+ Titrated into BvCTnC.  This data represents a fit 
to a “two set of sites” binding model and is the average of two experiments.   
  Average of 2 Data Sets Reference [21, 45-47] 
n1 2.33 (± 0.03)  
n2 1.28 (± 0.05)  
K1 1.3 (± 0.1) x 106 1 x 107 
K2 6 (± 1) x 104 1 x 105 
∆G1 (kcal/mol) -8.3 (± 0.1)  
∆G2 (kcal/mol) -6.5 (± 0.1)  
∆H1 (kcal/mol) -9.31 (± 0.04)  
∆H2 (kcal/mol) 14.3 (± 0.03)  
T∆S1 (kcal/mol)  -1.0 (± 0.1)  
T∆S2 (kcal/mol) 20.8 (± 0.2)  
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B)  Mg2+ Binding to apo BvCTnC 
We have also studied magnesium cations binding to the apo form of BVCTnC.  In vivo, 
Mg2+ is known to be displaced by calcium from the three calcium binding sites of cardiac 
troponin C and has a binding constant of 2 x 104 [21].  So, an appreciation of this divalent 
metal’s binding affinity to the apo form of the protein will be good reference to the literature as 
well as a good idea for how Ca2+ may displace the metal from the three binding sites so readily.   
An isotherm representing Mg2+ titrated into apo BvCTnC is shown in Figure 4.5.  The 
heat generated in this titration is endothermic and quite small.  Although it may appear that there 
is a slight sigmoidal nature to the binding curve, it is difficult to differentiate this heat from the 
heat of dilution observed in previous titrations.  The ITC data reveals that Mg2+ shows very weak 
binding, at best, and the data was not fit to any sort of binding model. 
 As previously mentioned, K values on the order of 104 have been observed for Mg2+ 
titrations into the apo form of BvCTnC [21].  Unfortunately, our data was not suitable for 
extracting thermodynamic values.  The heat of dilution overshadows any heat associated with 
magnesium ions binding to the protein.  A displacement reaction whereby Ca2+ replaces Mg2+ 
ions may yield data that will allow one to extract these parameters.   
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Figure 4.5.  A titration of Mg2+ (0.6 mM) into apo BvCTnC (9 µM). The data point highlighted 
in red appears to be an outlier.  Experiments were conducted at room temperature (25oC).  All 
protein and metal solutions were in 10 mM MES and 50 mM KCl at pH=7.0 buffer conditions.  
Aliquots were delivered in 8 µL injections with a spacing of 250 s in between each injection.  
The stirring speed for the ITC was 307 rpm. 
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C) Ca2+ Binding to BvCTnC in the Presence of Magnesium 
A displacement reaction whereby Ca2+ replaces Mg2+ ions was attempted in hopes that it 
would allow us to indirectly extract these parameters.  A representative titration curve for Ca2+ 
ions binding to BvCTnC in the presence of Mg2+ (0.l mM) is shown in Figure 4.6.  The figure 
shows a binding isotherm that is identical to that obtained for Ca2+ binding to the apo form of 
BvCTnC.  The data in Figure 4.6 was fit to a “two set of sites” binding model and 
thermodynamic values are listed in Table 4.3.  These thermodynamic parameters are highly 
consistent with data for Ca2+ binding to the apo form of BvCTnC found in Table 4.2.  This data 
demonstrates that the presence of Mg2+ at 0.1 mM concentrations does not interfere with Ca2+ 
binding to BvCTnC.  Future studies include repeating experiments with larger concentrations of 
Mg2+ present. 
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Figure 4.6.  A titration of Ca2+ (0.6 mM) into BvCTnC (9 µM) in the presence of Mg2+ (0.1 
mM).  This data set is fit to a “two set of sites” binding model.  Experiments were conducted at 
room temperature (25oC).  All protein and metal solutions were in 10 mM MES and 50 mM KCl 
at pH=7.0 buffer conditions.  Aliquots were delivered in 8 µL injections with a spacing of 250 s 
in between each injection.  The stirring speed for the ITC was 307 rpm. 
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Table 4.3. Titration of calcium into BvCTnC after magnesium has been added.  This data set is 
fit to a “two set of sites” binding model. 
Thermodynamic Binding Parameters  
n1a 2.03 (± 0.02) 
n2a,b 1.10 (± 0) 
K1a 1.37 (± 0.12) x 106 
K2a,b 4.50 (± 0) x 104
∆G1 (kcal/mol) -8.37 
∆G2 (kcal/mol) -6.28 
∆H1 (kcal/mol)a -8.6 (± 0.2) 
∆H2 (kcal/mol)a 15.3 (± 0.5) 
T∆S1 (kcal/mol)  -0.23  
T∆S2 (kcal/mol) 21.58 
 
a. Error values were taken from Origin and reflect the error in the fit values. 
b. An error of zero means that the parameter was fixed during the fitting procedure and not 
allowed to float 
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4.4 Human Cardiac TnC (HCTnC) 
The human cardiac troponin C is, by far, the most interesting and valuable form of the 
protein.  A thermodynamic investigation of divalent metal binding to the protein is essential in 
understanding the mechanism by which the protein binds calcium.  A better appreciation of the 
mechanism can help drug developers develop better “calcium sensitizers.”  
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A) Ca2+ Binding to HCTnC 
A representative isotherm of a Ca2+ titration into apo HCTnC is shown in Figure 4.7.  
The binding isotherm is, in general, similar to isotherms obtained from the bovine form of the 
protein.  Both titrations begin with an exothermic heat event (-8 kcal/mol) that transitions into an 
endothermic heat event during the course of the experiment.  At a molar ratio of 4.5, the protein 
becomes saturated with calcium, and the signal observed matches the heat of dilution of calcium 
into buffer.  The exothermic phase of both titrations correspond to the binding of 2 calcium ions 
to the high affinity sites of the protein, while the endothermic phase is indicative of calcium 
binding to low affinity regulatory domain.  Upon close inspection of the binding isotherm, there 
appears to be a clear distinction between Ca2+ binding to the 2 structural C domain sites in the 
protein with inflections occurring at a molar ratio of approximately 1 and 2. 
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Figure 4.7.  A titration of Ca2+ (1 mM) into apo HCTnC (44.6 µM).  Data was fit using a 
sequential set of sites binding model.  Experiments were conducted at room temperature (25oC).  
All protein and metal solutions were in 10 mM MES and 50 mM KCl at pH=7.0 buffer 
conditions.  Aliquots were delivered in 8 µL injections with a spacing of 250 s in between each 
injection.  The stirring speed for the ITC was 307 rpm. 
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Table 4.4.  Titration of Calcium into the apo form of HCTnC.  This data set is fit to a sequential 
set of sites binding model. 
 Thermodynamic Parameters Average of 2 Data Sets Reference [20, 45-47] 
K1 1.03 (± 0.04) x 106 1 x 107 
K2 2.0 (± 0.4) x 105 1 x 107 
K3 3.8 (± 0.9) x 105 1 x 105 
∆G1 (kcal/mol) -8.2 (± 0.8)  
∆G2 (kcal/mol) -7.2 (± 0.1)  
∆G3 (kcal/mol) -7.6 (± 0.1)  
∆H1 (kcal/mol) -8.6 (± 0.4)  
∆H2 (kcal/mol) -5.5 (± 0.4)  
∆H3 (kcal/mol)  5 (± 1)  
T∆S1 (kcal/mol)  -0.44 (± 0.36)  
T∆S2 (kcal/mol) 1.7 (± 0.6)  
T∆S3 (kcal/mol)  13 (± 1)  
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As discussed in chapter 3, the binding constants in a “sequential set of sites” model are 
defined relative to the progress of saturation as seen in Eqs. 28-30. 
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Eqs. 28-30 
The mechanism of metal binding to calmodulin, troponin, and other calcium-binding 
proteins has been widely investigated using fluorescence, ESI-MS techniques, and 
microcalorimetric studies [45-47, 50-51].  Data for calmodulin supports a cooperative binding 
mechanism that suggests a coupling between the four sites and two lobes of calmodulin [49].  A 
“sequential set of sites” model was therefore the best choice for fitting this data and the data is 
compiled in Table 4.4.  
Addition of the first Ca2+ to HCTnC displays a binding constant, K1, of 1.03 (± 0.04) x 
106 which agrees quite closely to that found of BvCTnC (K1 = 1.3 (± 0.1) x 106).  These binding 
constant are 1 order of magnitude smaller than what is observed in the literature [21, 45-47].  
The differences in binding constant values may stem from differences in buffers, buffer 
concentrations, ionic strength, and pH levels.  Also, the values are closer to the Yamada paper 
when the temperature in increased [46].  In addition, the binding enthalpy ΔH1 associated with 
the binding of the first ligand to the protein agrees quite nicely with that found for BvCTnC (-
9.31 (± 0.04) kcal/mol) and differs by only a factor of 1.1.  The TΔS1 for this process was 
calculated to be -0.440 (± 0.362) kcal/mol.  This differs from the value obtained for BvCTnC (-
1.0 (± 0.1) kcal/mol) by a factor of two.  The ΔG1 was determined to be -8.2 (± 0.8) kcal/mol 
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which is very favorable.  As a result, the binding of the first calcium ion to the protein is an 
enthalpically driven process.   
The second calcium ion is shown to bind with a K2 = 2.0 (± 0.4) x 105 and ΔH2 = -5.5 (± 
0.4) kcal/mol.  This is the first time that the binding of the second calcium ion has been distinctly 
observed by ITC for an EF handed protein.  This contrasts data obtained for BvCTnC where 
binding of both ligands to the high affinity sites of the protein were indistinguishable.  It is not 
clear as to whether this is due to differences in the amino acid sequences between BvCTnC and 
HCTnC or if the second binding was just not resolved in the BvCTnC titrations.  Titrations 
involving BvCTnC were run at 10 μM concentrations, while titrations of HCTnC were run at 
much high concentrations (44 μM).  ΔG2 was found to be -7.2 (± 0.1) kcal/mol and energetically 
favorable.  The entropy for this process was favorable as well with TΔS2 = 1.7 (± 0.6) kcal/mol.  
It is interesting to note that the binding constant obtained for calcium binding to the first site is 
an order of magnitude larger than binding to the second site.  If both sites are identical, this 
would indicate a negative cooperativity between the two sites. 
Binding of the third and final calcium to the protein is more comparable with that of the 
bovine titrations under the same conditions.  The binding constant K3 is 3.8 (± 0.9) x 105 and 
agrees closely with the literature value of the low affinity site (1 x 105) [21].  The overall ΔG3 for 
this process is -7.6 (± 0.1) kcal/mol and energetically favorable as in the case of BvCTnC.  ΔH3 
and ΔS3 were found to be 5 (± 1) and 13 (± 1) kcal/mol respectively which differ from the 
BvCTnC values by a factor of 2 in each case.  Again, this data reveals that binding of the third 
calcium is an entropically favored process.   
 
73 
 
4.5 Bepridil 
A fundamental thermodynamic understanding of Bepridil’s binding mechanism to 
cardiac troponin subunit C can reveal a multitude of answers regarding calcium sensitizers’ 
viability as a drug treatment for familial hypertrophic cardiomyopathy.  The following 
isothermal titration calorimetry experiments and discussions hopefully serve to answer some of 
these questions regarding Bepridil and calcium sensitizing drugs’ mechanism of action.   
Bepridil is known to make troponin more sensitive to the presence of calcium as a 
“calcium sensitizer.”  Bepridil is also acknowledged to only bind to troponin in the presence of 
calcium.  As discussed in the previous chapter, Bepridil binds three equivalents to the C subunit 
of troponin in isolation [42].  When the entire complex of troponin is present, Bepridil has only 
been shown to bind one equivalent.  Our study will only focus on the C subunit of troponin. 
Possibly the most important experiments in terms of understanding the mechanism by 
which Bepridil binds to cardiac troponin subunit C are the titrations involving Bepridil with the 
human form of the protein.  We were able to get successful titration data where one can observe 
the binding of the three equivalents of Bepridil to the calcium saturated form of the protein.  This 
process was not easy.  Bepridil is not very soluble in water and must first be diluted in ethanol 
before going into solution.  pH is another issue associated with Bepridil.  Bepridil needs to be at 
a relatively low pH in order for it to stay in solution and not precipitate out of the solution.  Our 
threshold of pH allowed for us to be the closest to a neutral pH that we could be without the drug 
crashing out of solution.  A pH of 5.7 was used in all Bepridil titrations.  We also made sure that 
the pH of the protein was the same so as to only detect heats associated with the binding of the 
drug to the protein.   
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A) Bepridil Binding to HCTnC 
Figure 4.8 displays a typical binding isotherm found when titrating Bepridil into HCTnC 
in the presence of 10 mM CaCl2.  The isotherm looks very different from those obtained in the 
calcium binding experiments.  The titration produced solely exothermic peaks that reached heat 
of dilution at a molar ratio of 7.  The titrations were not extended further.  The isotherm does not 
display predominant features, but upon closer inspection it appears to have two phases.  The first 
phase in the isotherm is characterized by a steep slope which tapers off at a molar ratio of 2.  
This phase is followed by a gentler slope that slowly reaches heat of dilution.   
As mentioned previously, 3 Bepridil molecules bind to CTnC in the absence of the TnI 
and TnT subunits [42].  More specifically, x-ray crystal structures have revealed two Bepridil 
molecules bind to the C lobe of the protein whereas the third molecule binds to the N lobe of the 
protein [42].  It is not known what the order of the binding is or if there is cooperativity between 
the binding sites.  Fitting the data to the simplest model available to us, the “one set of sites” 
model, did not result in a proper fit to the data.  We chose the “two set of sites” model because 
there were only 2 discernable phases in the data retrieved.  This does not necessarily mean that 
there are only 2 Bepridil molecules that bind, but it appears that there are only two phases of 
binding which may mean the binding of 2 Bepridil molecules shadow one another.  The 
thermodynamic data is compiled in Table 4.5. 
Binding of Bepridil molecules to HCTnC is an energetically favorable process in two 
phases as noted by the ΔG values in Table 4.5.  Binding constants for the processes are on the 
order of 105 (1st phase) and 104 (2nd phase).  Both binding constants reveal enthalpically driven 
processes with ΔH1 and ΔH2 values of -16.16 (± 4.34) kcal/mol and -27.17 (± 5.76) kcal/mol, 
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respectively.  Entropy was disfavored in these two processes with TΔS values equal to -10.22 (± 
4.32) and -20 (± 6.02) kcal/mol for each binding event. 
 
 
 
 
76 
 
0 1 2 3 4 5 6 7
-14
-12
-10
-8
-6
-4
-2
0
-0.8
-0.6
-0.4
-0.2
0.0
0 30 60 90 120 150
Time (min)
µc
al
/s
ec
Molar Ratio
kc
al
/m
ol
e 
of
 in
je
ct
an
t
 
Figure 4.8. A titration of Bepridil (0.295 mM) into HCTnC (9 µM) containing CaCl2 (10 mM).  
Bepridil stocks were dissolved in 5% EtOH. Experiments were conducted at room temperature 
(25oC).  All protein and metal solutions were in 10 mM MES and 50 mM KCl at pH=5.7 buffer 
conditions.  All solutions were matched with identical amounts of EtOH.  Aliquots were 
delivered in 8 µL injections with a spacing of 250 s in between each injection to ensure 
equilibration.  The stirring speed for the ITC was 307 rpm. 
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Table 4.5. Thermodynamic Properties of Bepridil Titrated into HCTnC with Ca2+ Present. 
Thermodynamic Parameters Average of 2 Data Sets 
n1 1 (± 0) 
n2 0.62 (± 0.05) 
K1 2.23 (± 0) x 104 
K2 1.97 (± 0.85) x 105 
β 4.39 (± 0.85) x 109 
∆G1 (kcal/mol) -5.92 (± 0)
∆G2 (kcal/mol) -7.17 (± 0.27)
∆H1 (kcal/mol) -16.16 (± 4.34) 
∆H2 (kcal/mol) -27.17 (± 5.76) 
T∆S1 (kcal/mol) -10.22 (± 4.32) 
T∆S2 (kcal/mol) -20.00 (± 6.02) 
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 Based on our data, it is not possible to deduce a third binding event in the binding 
isotherm or in the raw data.  There are only two phases of binding occurring and it is not possible 
to discern a third binding event in the data.  Early NMR studies suggest very large changes in the 
protein upon binding up to 1 equivalent of Bepridil [40].  These changes become less 
pronounced upon binding additional equivalents.  Furthermore, these changes occur in the 
spectral regions that correspond to the regulatory domain of the protein.  According to the NMR 
structure, binding of Bepridil to the regulatory domain (N Lobe) results in a large conformational 
change [40].  This change opens the regulatory lobe and exposes a hydrophobic patch [40].  
Based on this information, we hypothesize that the first set of thermodynamic parameters refers 
to the binding of a Bepridil molecule to the N domain region of the protein.  To verify this, it 
would be worthwhile to study the truncated N domain form of the protein for comparison.   
 The sequential mechanism of Bepridil binding to a TnC protein is shown in scheme 1. 
 
Scheme 1. 
The overall binding reaction and binding constant, β, for 3 Bepridil molecules binding to TnC is 
represented by Equations 31 and 32 respectively. 
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Eq. 31 
? ? ????? ? ???????????????  
Eq. 32 
The β value can be calculated according to the following expression. 
K1 x K2 = β 
Eq. 33 
 The β value for this process was found to be 4.39 x 109.  Early studies report an apparent 
binding constant of 1 x 105 for Bepridil binding to CTnC by fluorescent methods [52].  It is 
important to note that the conditions under which these experiments were run differed from ours 
and also did not account for competing reactions.  It is also important to note that our value 
represents two Bepridil binding events to the protein and is not relevant physiologically. 
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4.6 Conclusions 
A) Divalent Metal Binding Conclusions 
I. Calcium Binding (BvCTnC) 
 The K1 for the “two set of sites” model and the K1/K2 for the “sequential 
set of sites” model is an order of magnitude less than what is reported in 
the literature, but closer to the Yamada paper value when done at a 
similar temperature and using similar techniques 
 The K2 for the “two set of sites” model and the K3 for the “sequential set 
of sites” model agrees well with the literature. 
 The binding of the two high affinity sites are enthalpically driven 
processes. 
 The binding of the low affinity site is an entropically driven process. 
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II.  Magnesium Binding (BvCTnC) 
 The ITC experiments where magnesium is titrated into the apo form of 
the protein proved unsuccessful.  This may be an indication that the 
heats associated with the binding events are beyond the threshold of the 
instrument. 
 The experiments where Mg2+ is displaced by Ca2+ from the three binding 
sites were done at low concentrations of Mg2+.  Future studies may look 
to increase the concentration of Mg2+ to properly report thermodynamic 
properties associated with competition for the binding sites. 
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III. Calcium Binding (HCTnC) 
 Unique because thermodynamic parameters were extracted for the 
binding events of each of the three calcium ions to the apo form of 
HCTnC. 
 The 3rd site is an entropically driven process and sites 1 and 2 are 
enthalpically driven processes. 
 It is interesting to note that K1 > K2 because it implies that binding of 
calcium is not cooperative and binding of the first calcium weakens the 
binding of the second calcium.   
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B) Bepridil Binding Conclusions 
 Binding of Bepridil to HCTnC occurs in two phases. 
 The two binding events appear to be enthalpically driven processes. 
 One binding event binds with a higher affinity than the other. 
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C) Future Directions 
The calcium and Bepridil ITC studies with bovine and human forms of the cardiac TnC 
protein have produced very interesting results.  ITC has allowed us to directly observe and 
quantify, for the first time, the ΔH and ΔS of binding to this system.  In particular, experiments 
revealed that calcium binding to the regulatory domain is an entropically driven process.  This 
was not expected in light of the fact that a hydrophobic patch is exposed upon calcium binding to 
the N domain.  This has forced us to think more deeply about the other changes in the protein 
that occur upon calcium binding to the regulatory domain of CTnC and has opened up a very 
important question.  Are the thermodynamics of Ca2+ binding to the N domain affected by the 
presence of the C domain?  In the absence of the C domain, will we see the same thermodynamic 
parameters for Ca2+ binding to the regulatory domain as observed in the full length protein?   
We have recently obtained the construct for the truncated form of HCTnC which consists 
of the N domain region, residues 1-89.  Future studies include over-expressing and purifying this 
protein according to already published procedures [53] and investigating its calcium and Bepridil 
binding properties. 
Future studies also include investigating other possible “calcium sensitizing” drug 
molecules.  Dr. Li and Dr. Huo are computationally designing and formulating new drugs that 
may fit as drugs to treat this disorder.  Our first attempts at studying such molecules were 
unsuccessful.  This was mainly due to solubility issues which need to be resolved. 
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Appendix A 
 
 
A) Supplemental gel to compare to Figure 4.1.  Similar conditions to the gel reported previously 
in the thesis. 
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B) Supplemental to compare to Figure 4.1.  Similar conditions to the gel reported previously in 
the thesis. 
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C) Supplemental data to compare to Figure 4.3.  A titration of Ca2+ (0.6 mM) into apo BvCTnC 
(10 µM).  Experiments were conducted at room temperature (25oC).  All protein and metal 
solutions were in 10 mM MES and 50 mM KCl at pH=7.0 buffer conditions.  Aliquots were 
delivered in 8 µL injections with a spacing of 250 s in between each injection.  The stirring speed 
for the ITC was 307 rpm.  This data set was fit to a “two set of sites” binding model. 
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D) Supplemental data to compare to Figure 4.3.  A titration of Ca2+ (1 mM) into apo BvCTnC 
(10 µM).  Experiments were conducted at room temperature (25oC).  All protein and metal 
solutions were in 10 mM MES and 50 mM KCl at pH=7.0 buffer conditions.  Aliquots were 
delivered in 8 µL injections with a spacing of 250 s in between each injection.  The stirring speed 
for the ITC was 307 rpm.  This data set was fit to a “two set of sites” binding model. 
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E) Supplemental data to compare to Figure 4.4. A titration of Ca2+ (0.6 mM) into apo BvCTnC 
(10 µM).  Experiments were conducted at room temperature (25oC).  All protein and metal 
solutions were in 10 mM MES and 50 mM KCl at pH=7.0 buffer conditions.  Aliquots were 
delivered in 8 µL injections with a spacing of 250 s in between each injection.  The stirring speed 
for the ITC was 307 rpm.  This data set was fit to a “sequential set of sites” binding model. 
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F) Supplemental data to compare to Figure 4.4.  A titration of Ca2+ (1 mM) into apo BvCTnC 
(10 µM).  Experiments were conducted at room temperature (25oC).  All protein and metal 
solutions were in 10 mM MES and 50 mM KCl at pH=7.0 buffer conditions.  Aliquots were 
delivered in 8 µL injections with a spacing of 250 s in between each injection.  The stirring speed 
for the ITC was 307 rpm.  This data set was fit to a “sequential set of sites” binding model. 
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G) Supplemental data to compare to Figure 4.7.  A titration of Ca2+ (1 mM) into apo HCTnC 
(44.6 µM).  Data was fit using a sequential set of sites binding model.  Experiments were 
conducted at room temperature (25oC).  All protein and metal solutions were in 10 mM MES and 
50 mM KCl at pH=7.0 buffer conditions.  Aliquots were delivered in 8 µL injections with a 
spacing of 250 s in between each injection.  The stirring speed for the ITC was 307 rpm. 
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H) Supplemental data to compare to Figure 4.7.  A titration of Ca2+ (0.7 mM) into apo HCTnC 
(44.6 µM).  Data was fit using a sequential set of sites binding model.  Experiments were 
conducted at room temperature (25oC).  All protein and metal solutions were in 10 mM MES and 
50 mM KCl at pH=7.0 buffer conditions.  Aliquots were delivered in 8 µL injections with a 
spacing of 250 s in between each injection.  The stirring speed for the ITC was 307 rpm. 
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I) Supplemental data to compare to Figure 4.8.  A titration of Bepridil (0.295 mM) into HCTnC 
(9 µM) containing CaCl2 (10 mM).  Bepridil stocks were dissolved in 5% EtOH. Experiments 
were conducted at room temperature (25oC).  All protein and metal solutions were in 10 mM 
MES and 50 mM KCl at pH=5.7 buffer conditions.  All solutions were matched with identical 
amounts of EtOH.  Aliquots were delivered in 8 µL injections with a spacing of 250 s in between 
each injection to ensure equilibration.  The stirring speed for the ITC was 307 rpm. 
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J) Supplemental data to compare to Figure 4.8.  A titration of Bepridil (0.295 mM) into HCTnC 
(9 µM) containing CaCl2 (10 mM).  Bepridil stocks were dissolved in 5% EtOH. Experiments 
were conducted at room temperature (25oC).  All protein and metal solutions were in 10 mM 
MES and 50 mM KCl at pH=5.7 buffer conditions.  All solutions were matched with identical 
amounts of EtOH.  Aliquots were delivered in 8 µL injections with a spacing of 250 s in between 
each injection to ensure equilibration.  The stirring speed for the ITC was 307 rpm. 
